| Source: |
| Type: |
| Event-Free Survival - EFS Type: Clinical outcome / oncology efficacy endpoint Function: Event-Free Survival is the time from a defined starting point, such as diagnosis, treatment initiation, or randomization, until the occurrence of a prespecified adverse event. Depending on the study, events may include disease progression, relapse, treatment failure, development of a second malignancy, or death from any cause. Cancer: ↑ Longer EFS indicates a longer period without a predefined adverse clinical event and is therefore generally favorable. ↓ EFS indicates earlier progression, relapse, treatment failure, second malignancy, death, or another protocol-defined event and is unfavorable. Favorable Direction: ↑ Longer Event-Free Survival. Interpretation Note: The exact definition of an "event" varies between clinical trials, so EFS values should be interpreted using the event criteria specified by the individual study. |
| 8173- | Lap, | Tras, | Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials |
| - | Review, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1773 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid